Abstract

Cancer cells exhibit remarkable alterations in cellular metabolism, particularly in their nutrient substrate preference. We have devised several experimental methods that rapidly analyze the metabolic substrate flux in cancer cells: glycolysis and the oxidation of major fuel substrates glucose, glutamine, and fatty acids. Using the XF Extracellular Flux analyzer, these methods measure, in real-time, the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of living cells in a microplate as they respond to substrates and metabolic perturbation agents. In proof-of-principle experiments, we analyzed substrate flux and mitochondrial bioenergetics of two human glioblastoma cell lines, SF188s and SF188f, which were derived from the same parental cell line but proliferate at slow and fast rates, respectively. These analyses led to three interesting observations: 1) both cell lines respired effectively with substantial endogenous substrate respiration; 2) SF188f cells underwent a significant shift from glycolytic to oxidative metabolism, along with a high rate of glutamine oxidation relative to SF188s cells; and 3) the mitochondrial proton leak-linked respiration of SF188f cells increased significantly compared to SF188s cells. It is plausible that the proton leak of SF188f cells may play a role in allowing continuous glutamine-fueled anaplerotic TCA cycle flux by partially uncoupling the TCA cycle from oxidative phosphorylation. Taken together, these rapid, sensitive and high-throughput substrate flux analysis methods introduce highly valuable approaches for developing a greater understanding of genetic and epigenetic pathways that regulate cellular metabolism, and the development of therapies that target cancer metabolism.

Highlights

  • Cancer cells significantly reprogram their metabolism to drive tumor growth and survival

  • Glycolysis and glycolytic capacity We have previously shown that glycolysis accounts for,80% of total ECAR in a number of cancer cells as determined through two methods: a) removing glucose from the assay medium and b) adding glycolytic pathway inhibitors such as hexokinase inhibitor 2-DG and lactate dehydrogenase (LDH) inhibitor oxamate [22]

  • The remaining 20% of the ECAR can be attributed to other metabolic processes, such as the TCA cycle CO2 evolution

Read more

Summary

Introduction

Cancer cells significantly reprogram their metabolism to drive tumor growth and survival. A large body of evidence indicates that cancer cells undergo metabolic reprogramming, leading to extensive use of and dependence upon glucose or glutamine for their growth and survival [3,4,5,6,7,8,9]. This metabolic reprogramming has been shown to be the result of oncogene activation and/or loss of tumor suppressor functions, as well as in response to environmental cues, all of which regulate nutrient substrate uptake and metabolism [10,11,12,13,14]. Depending on the combinations of these factors and a given cellular context, cancer cells can manifest an array of metabolic phenotypes [15] , which may impact either treatment selection or response to treatment

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call